Abstract
The authors investigated the safety of 75 mg/m2 temozolomide for 21 days every 28 days in glioma patients. This schedule could lead to DNA repair enzyme O6-alkylguanine-DNA alkyltransferase depletion, contributing to overcoming drug resistance. Although Phase III studies are forthcoming, no data are available on the long-term toxicity of temozolomide, which, in this series, incurred prolonged, cumulative lymphopenia, which leads to a high incidence of infections.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents, Alkylating / administration & dosage*
-
Antineoplastic Agents, Alkylating / adverse effects
-
Antineoplastic Agents, Alkylating / therapeutic use
-
Central Nervous System Neoplasms / drug therapy*
-
Dacarbazine / administration & dosage
-
Dacarbazine / adverse effects
-
Dacarbazine / analogs & derivatives*
-
Dacarbazine / therapeutic use
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Feasibility Studies
-
Female
-
Glioma / drug therapy*
-
Humans
-
Infections / etiology
-
Lymphopenia / chemically induced*
-
Lymphopenia / complications
-
Male
-
Middle Aged
-
Temozolomide
Substances
-
Antineoplastic Agents, Alkylating
-
Dacarbazine
-
Temozolomide